Orchestra BioMed Gains Access to $12.2 Trillion Russell 3000 and 2000 Indexes
OBIO•Orchestra BioMed joined the Russell 3000 and small-cap Russell 2000 indexes following the 2026 semi-annual reconstitution effective June 26, granting automatic inclusion in growth and value style benchmarks. Russell's U.S. benchmarks collectively track $12.2 trillion in assets, potentially increasing institutional demand and liquidity for Orchestra BioMed shares.
1. Index Inclusion Details
Orchestra BioMed qualified for inclusion in the Russell 3000 and Russell 2000 indexes after the April 30 market-capitalization ranking, with changes taking effect following the US market close on June 26. Membership in the all-cap Russell 3000 triggers automatic placement in the small-cap Russell 2000 as well as corresponding growth and value style indexes.
2. Potential Market Impact
Russell's U.S. indexes serve as benchmarks for investment managers and institutional funds overseeing approximately $12.2 trillion in assets. Inclusion may prompt index-tracking funds to acquire Orchestra BioMed shares, enhancing trading volume and liquidity while potentially narrowing bid-ask spreads.
3. Company Profile
Orchestra BioMed is developing two lead product candidates—AVIM Therapy for hypertension and Virtue Sirolimus AngioInfusion Balloon—both in pivotal clinical trials and representing multi-billion-dollar market opportunities. The company has a strategic collaboration with Medtronic and has secured FDA Breakthrough Device Designations for its flagship technologies.
